A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

Martina Eriksen*, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Camilla Qvortrup

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study'. Together they form a unique fingerprint.

Medicine & Life Sciences